Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NCI

- PMLiVE

Lynparza set for further expansion with EU approval in breast cancer

Companies have prostate cancer and pancreatic cancer in their sights

- PMLiVE

Celgene files luspatercept ahead of key merger vote

Analysts predict peak revenues of $2bn

- PMLiVE

Second chance for AstraZeneca’s selumetinib with breakthrough designation

Part of R&D and commercial collaboration with MSD

Bristol Myers Squibb logo

BMS closes on Celgene merger after rebel investors bow out

News on Revlimid patent also positive

- PMLiVE

NICE green light for Imfinzi in groundbreaking early lung cancer treatment

Early treatment opens up possibility of cure

- PMLiVE

Trump takes aim at Obamacare with repeal move

Aims to dismantle the programme

Celgene building

Celgene hopes for second time lucky for ozanimod FDA filing

One of six key drugs for BMS-Celgene merger

- PMLiVE

Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity

Firm says it cuts discovery timelines by 75%

- PMLiVE

Novo uses voucher for speedy answer on oral semaglutide

Oral version of Ozempic could be diabetes market leader

Bristol Myers Squibb logo

BMS defends Celgene buyout ahead of shareholder vote

BMS battles for hearts and minds before shareholder vote

- PMLiVE

Celgene’s Abraxane fails pancreatic cancer trial

Abraxane failed to show improvement in disease-free survival

Bristol-Myers Squibb (BMS) building

BMS trades blows with investor on Celgene deal merits

Activist investors claim Celgene’s pipeline is “extremely risky”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links